CD274 and non-small cell lung carcinoma: Accumulating evidence and our previous studies indicated that immune checkpoint inhibitors (ICIs) represented by anti-programmed cell death ligand 1 (PD-L1) inhibitors are novel promising neoadjuvant therapies for advanced-stage NSCLC and have brought some success to the treatment of NSCLC [5,6].